Core Insights - Opus Genetics, Inc. has launched a clinical trial for a gene therapy targeting MERTK-related retinitis pigmentosa, a rare inherited eye disease that leads to progressive vision loss and blindness [1][3][4] Company Overview - Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases (IRDs) [6][8] - The company is working on a pipeline that includes seven AAV-based programs, with OPGx-MERTK being a key candidate for MERTK-related retinitis pigmentosa [6][8] Clinical Trial Details - The clinical trial will assess the safety and efficacy of OPGx-MERTK, which uses an adeno-associated virus (AAV) to deliver a functional copy of the MERTK gene to retinal cells [3][4] - The trial is set to begin in 2026 at Cleveland Clinic Abu Dhabi, which will serve as the clinical site [2][7] Collaboration and Impact - The trial is being conducted in collaboration with the Department of Health – Abu Dhabi, Cleveland Clinic Abu Dhabi, and other local partners, highlighting Abu Dhabi's commitment to precision medicine and rare disease innovation [2][5] - MERTK-related retinitis pigmentosa affects approximately 60,000 patients globally, and this trial represents a significant opportunity to address an unmet medical need [4][7]
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa